Navigation Links
Discovery of 100 million-year-old regions of DNA shows short cut to crop science advances
Date:12/5/2012

Scientists have discovered 100 million-year-old regions in the DNA of several plant species which could hold secrets about how specific genes are turned 'on' or 'off'.

The findings, which are hoped will accelerate the pace of research into crop science and food security, are detailed by University of Warwick researchers in the journal The Plant Cell.

By running a computational analysis of the genomes of the papaya, poplar, Arabidopsis and grape species, scientists have uncovered hundreds of conserved non-coding sequences which are found in the DNA of all four species.

These non-coding sequences are not genes, but are located in the promoters upstream of genes and are around 100 DNA base pairs in length.

As the four species have evolved separately for around 100 million years, the fact that these regions have been conserved suggests they play an important role in the plants' development and functioning.

The team at the University of Warwick believe these regions are involved in controlling the expression of the genes they are upstream of - in other words determining whether the genes are turned 'on' or 'off' according to the environmental conditions or developmental stage of the plant.

For example, some genes will be required for defence against pathogens, or others will be required for germination.

Dr Sascha Ott of the Warwick Systems Biology Centre said: "We know that certain genes are conserved between species but we also see that sequences outside of genes are conserved.

"The regions outside genes that we have discovered have been kept for millions and millions of years across four species.

"There must be a reason for this if something has been around for so long it is probably useful in some way.

"We believe it may be because these regions have a very important role to play in how the plant develops and functions.

"It is likely that they are involved in controlling gene expression a vital area fo
'/>"/>

Contact: Anna Blackaby
a.blackaby@warwick.ac.uk
44-024-765-75910
University of Warwick
Source:Eurekalert

Page: 1 2

Related biology news :

1. Discovery of molecular pathway of Alzheimers disease reveals new drug targets
2. The Journal of Biological Chemistry commemorates an important 1987 discovery
3. GW Research chosen as paper of the week for blood coagulation discovery
4. NIH-funded genetic sequencing tool speeds drug discovery, disease diagnostics
5. Discovery of reprogramming signature may help further stem cell-based regenerative medicine research
6. King Richard III search in new phase after discovery has potential to rewrite history
7. New discovery related to gum disease
8. Cant smell anything? This discovery may give you hope
9. Chemicals today, drugs tomorrow: U-Ms new Center for Drug Discovery
10. Molecular movies may accelerate anti-cancer drug discovery
11. Gene discovery could improve treatment for acute myeloid leukemia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/6/2015)... 2015 NXT-ID, Inc. (NASDAQ: NXTD ) ... focused on the growing mobile commerce market, announced ... for MINIATURE, MULTI-PURPOSE ANTENNA METHOD AND SYSTEM ... NXT-ID introduces a new revolutionary method and system ... use of miniature antenna modules for multiple purposes ...
(Date:4/2/2015)... -- According to preliminary estimates Fingerprint Cards, ... than 125 MSEK. This exceeds the guidance provided by ... for Q1 2015 would be in line with the ... The operating result for the first quarter is estimated ... will as previously communicated be published on May 21. ...
(Date:4/1/2015)... , April 1, 2015   Medisafe ™, ... million users across iOS and Android ... begun integrating biofeedback into the platform to allow patients ... outcomes. For the first time, patients will be able ... a dose impacts important biometrics, such as glucose levels ...
Breaking Biology News(10 mins):NXT-ID Patents Miniature, Low Power Wireless Magnetic Stripe 2NXT-ID Patents Miniature, Low Power Wireless Magnetic Stripe 3NXT-ID Patents Miniature, Low Power Wireless Magnetic Stripe 4Fingerprint Cards Revises Revenues for Q1 2015 2Medisafe Announces Launch of Biometric Integration, Enabling Patients to Stay Adherent to Their Meds and See Tangible Health Results 2
... the way to go, if you are a primate crossing ... researchers have measured the energy required to navigate a forest ... in the trees. Their work was presented at the Society ... 2012. The findings help us to understand why ...
... discovered that recent climate change is causing leaves of some ... is the first of its kind in the world, highlights ... The results are published online today in the Royal ... analysed leaves from herbarium specimens of Narrow-leaf Hopbush ( Dodonaea ...
... resource developed at the San Diego Supercomputer Center ... is helping thousands of researchers worldwide unravel the ... among virtually every species on the planet. ... Infrastructure for Phylogenetic RESearch), created by SDSC researchers, ...
Cached Biology News:Shrinking leaves point to climate change 2SDSC's CIPRES Science Gateway clarifies branches in evolution's 'tree of life' 2SDSC's CIPRES Science Gateway clarifies branches in evolution's 'tree of life' 3
(Date:4/27/2015)... 2015 /PRNewswire/ - iCo Therapeutics ("iCo" or "the Company") ... for the year ended December 31, 2014. Amounts, ... and presented under International Financial Reporting Standards ("IFRS"). ... did not provide the outcome management and investors ... at iCo Therapeutics", said Andrew Rae , ...
(Date:4/27/2015)... April 27, 2015  Edico Genome today announced ... from Harvard and Stanford Universities showed the DRAGEN™ ... sequence with 300x depth of coverage by tenfold, ... 60 hours with standard software. "Processing ... especially for individual research and clinical labs, in ...
(Date:4/27/2015)... April 27, 2015 ... please scroll to bottom . Investor-Edge ... Pharmaceuticals Inc. (NASDAQ: LXRX ), Idera Pharmaceuticals ... (NASDAQ: SNTA ), Spectrum Pharmaceuticals Inc. (NASDAQ: ... MDVN ). Free research report on Lexicon Pharma ...
(Date:4/27/2015)... -- Haemonetics Corporation (NYSE: HAE ) today reported ... $226.5 million, down 6%.  Excluding currency impact, revenue ... reported a fourth quarter GAAP net loss of ... income, exclusive of transformation, restructuring and deal amortization ... and adjusted earnings per share were $0.47, up ...
Breaking Biology Technology:iCo Therapeutics Announces Year End 2014 Financial Results 2iCo Therapeutics Announces Year End 2014 Financial Results 3iCo Therapeutics Announces Year End 2014 Financial Results 4Edico Genome, in Collaboration with Researchers from Harvard and Stanford Universities, Speeds Analysis of Whole Genome Sequence with 300x Depth of Coverage Tenfold 2Edico Genome, in Collaboration with Researchers from Harvard and Stanford Universities, Speeds Analysis of Whole Genome Sequence with 300x Depth of Coverage Tenfold 3Market Updates on Biotech Stocks -- Lexicon Pharma, Idera Pharma, Synta Pharma, Spectrum Pharma, and Medivation 2Market Updates on Biotech Stocks -- Lexicon Pharma, Idera Pharma, Synta Pharma, Spectrum Pharma, and Medivation 3Market Updates on Biotech Stocks -- Lexicon Pharma, Idera Pharma, Synta Pharma, Spectrum Pharma, and Medivation 4Market Updates on Biotech Stocks -- Lexicon Pharma, Idera Pharma, Synta Pharma, Spectrum Pharma, and Medivation 5Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 2Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 3Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 4Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 5Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 6Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 7Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 8Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 9Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 10Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 11Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 12Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 13Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 14Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 15Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 16Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 17Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 18Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 19Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 20Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 21Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 22Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 23Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 24Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 25Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 26Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 27
... CITY , May 6 /PRNewswire-FirstCall/ - Aeterna ... late-stage drug development company specialized in oncology and endocrinology, ... Food and Drug Administration (FDA), orphan-drug designation for AEZS-108, ... ovarian cancer. AEZS-108 is currently in a Phase 2 ...
... Wheat aleurone is a novel wheat grain fraction ... clinical trials with ready-to-eat cereals and bread containing ... blood concentrations of tentatively beneficial compounds such as ... both associated with heart disease risk. It ...
... CHARLOTTE, N.C. , May 5 The untimely death ... addiction to the forefront of American media recently. The good news for ... pain relief. , , ... of those options is called radiofrequency thermocoagulation therapy. Used to treat pain ...
Cached Biology Technology:Aeterna Zentaris Receives Orphan-Drug Designation from the FDA for AEZS-108 in Ovarian Cancer 2Aeterna Zentaris Receives Orphan-Drug Designation from the FDA for AEZS-108 in Ovarian Cancer 3Medication Doesn't Have to be the Answer to Pain; Southeast Pain Care Offers Pill-free Pain Relief 2
... depletion cocktail is tailored to ... from suspensions of rat spleen ... the StemSep (or compatible 0.5 ... system. The CD4+ T cell ...
Preparation TW--Compatibility: Push-on end cap seals suitable up to 70 C only -Hybridization Tube for Model HB-1D -Comp Dim: 200 80 mm -Material: borosilicate glass -Mfr Desig: Techne FHB-12...
Preparation TW--Compatibility: no end cap seals -Hybridization Tube for Hybrigene -Comp Dim: 240 80 mm -Material: borosilicate glass -Mfr Desig: Techne FHB-15...
...
Biology Products: